Pascal Soriot, AstraZeneca's CEO, Gains Close to 9,000 Ordinary Shares via Performance Share Plan Payout

AstraZeneca, the global biopharmaceutical titan, have announced that its Chief Executive Officer, Pascal Soriot, has added almost 9,000 ordinary shares to his investment portfolio. This significant move occurred on 21 May 2025, as part of the AstraZeneca Performance Share Plan (AZPSP), which came into effect in 2020. Soriot has been a leading figure at the helm of AstraZeneca, helping shepherd the company towards ground-breaking discoveries in crucial medicinal sectors, from oncology to immunology. Now, his belief in the company’s direction is affirmed as he acquires more shares. The AZPSP, which rewards high-performing individuals within the company, in this case, led to 97% of the original award vesting, while the remaining unvested portion expired. Dividend reinvestment during the performance and holding periods, along with withholdings to meet tax obligations, resulted in a change in Soriot’s beneficial interest in AstraZeneca’s ordinary shares. The acquisition of these 8,970 shares is a positive move for Soriot, as it indicates strong faith in AstraZeneca’s future, reinforcing the leadership commitment to the company’s vision. So, while AstraZeneca continues propelling science-driven research and delivering leading prescription medicines to millions of patients worldwide, they also solidify the trust and investment of key leadership members, ensuring continued excellence within this biopharmaceutical titan. Additional details about the events are available via the company’s investor relations department and will be reported in accordance with the EU Market Abuse Regulation.